Treatment Optimization in Myelofibrosis: When to Adjust, When to Switch, and When to Wait

This session focuses on optimizing treatment strategies in myelofibrosis, emphasizing practical decision-making on when to adjust therapy, switch agents, or continue observation. Dr. John Mascarenhas will explore emerging data shaping current practice, including the evolving role of JAK inhibitors beyond ruxolitinib, management of suboptimal response, and approaches to treatment-related cytopenias. Recent advances from major hematology meetings highlight novel mechanism based agents and combination strategies aimed at deepening spleen response, improving symptom control and ultimately modifying disease course. The discussion will also address molecular risk stratification, timing of therapeutic transitions, and integration of transplant considerations.